Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3898411
Max Phase: Preclinical
Molecular Formula: C25H30F6N6
Molecular Weight: 528.54
Molecule Type: Small molecule
Associated Items:
ID: ALA3898411
Max Phase: Preclinical
Molecular Formula: C25H30F6N6
Molecular Weight: 528.54
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: FC(F)(F)c1cc(CN2CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC2)cc(C(F)(F)F)c1
Standard InChI: InChI=1S/C25H30F6N6/c26-24(27,28)19-13-18(14-20(15-19)25(29,30)31)17-34-9-11-36(12-10-34)22-16-21(35-5-1-2-6-35)32-23(33-22)37-7-3-4-8-37/h13-16H,1-12,17H2
Standard InChI Key: TWGFWBPIHYEITI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 528.54 | Molecular Weight (Monoisotopic): 528.2436 | AlogP: 5.04 | #Rotatable Bonds: 5 |
Polar Surface Area: 38.74 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 0 |
#RO5 Violations: 2 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 6.53 | CX LogP: 6.38 | CX LogD: 6.34 |
Aromatic Rings: 2 | Heavy Atoms: 37 | QED Weighted: 0.51 | Np Likeness Score: -1.38 |
1. Kent CR, Bryja M, Gustafson HA, Kawarski MY, Lenti G, Pierce EN, Knopp RC, Ceja V, Pati B, Walters DE, Karver CE.. (2016) Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases., 26 (22): [PMID:27777011] [10.1016/j.bmcl.2016.10.025] |
Source(1):